Anklesaria P
Targeted Genetics Corporation, Suite 100, 1100 Olive Way, Seattle, WA 98101, USA.
Curr Opin Mol Ther. 2000 Aug;2(4):426-32.
The current delineation of the molecular basis of cancer provides a strong rationale to consider gene therapy approaches for cancer as a complement to other cancer therapies. Phase III trials focused on adenoviral vector-mediated delivery of wild-type p53 to compliment p53 mutations were recently initiated for head and neck cancer and ovarian cancer. Clinical testing of the tumor inhibitory gene E1A, delivered by synthetic vectors is ongoing. Positive clinical data from these clinical studies will establish the use of gene therapy as a component of the multimodal treatment for certain cancers.
目前对癌症分子基础的描述为将癌症基因治疗方法视为其他癌症治疗的补充提供了有力依据。近期针对头颈癌和卵巢癌启动了Ⅲ期试验，重点是通过腺病毒载体介导递送野生型p53以补充p53突变。由合成载体递送的肿瘤抑制基因E1A的临床试验正在进行中。这些临床研究的阳性临床数据将确立基因治疗作为某些癌症多模式治疗组成部分的应用。
